Skip to main content

Table 4 Summary of results of radiotherapy treatment

From: Systematic review of non-surgical treatments for early Dupuytren’s disease

Author (year) Treatment

Total cohort of DD patients (hands)

Number of patients (hands) with early DD

Study type

Level of evidence (OCEBM) Prospective (P) Retrospective (R) Not stated (N)

Outcome measure

Results

Recurrence

Adverse events

Improved

No change

Deteriorated

Keilholz (1996) [14] Radiotherapy

(142 hands)

(129 hands)

Case series

4 (R)

Clinical assessment of consistency and size of nodule

102

25

2

Not reported

EORTCa Grade 1 and 2 toxicity for total cohort.

Lukacs (1978) [45] Radiotherapy

36

32

Case series

4 (N)

Clinical assessment of softening of nodules, contracture improvement

26

6

0

Not reported

Not reported

Hesselkamp (1981) [46] Radiotherapy

46

46

Case series

4 (N)

Clinical assessment of softening of nodules and cords

24

19

3

Not reported

63 % dry skin with desquamation, 24 % skin atrophy, pigmentation and telangiectasia.

Adamietz (2001) [47] Radiotherapy

99 (176 hands)

(156 hands)

Case series

4 (R)

Tubiana grade

18

79

59, (27 within and 32 outside RT field)

At 10 years >20 % N (n = 13), >20 % N/1 (n = 13), 65 % stage 1 (n = 30.

For total cohort of 176 hands at median 10 years, 44 reported strong desquamation and 15 cutaneous telangiectasia with subcutaneous atrophy.

Kohler (1984) [48] Radiotherapy

29 (33 hands)

29 (33 hands)

Case series

4 (N)

Clinical assessment of softening of DD tissue

7

20

6

1 outside the radiotherapy area.

Not reported

Weinzierl 1993) [49] Radiotherapy n = 34

39 (56 hands)

39 (56 hands)

2 Case series

4 (N)

Clinical assessment of consistency and size of nodules

3

14

17

Not reported

32 % had small but ongoing skin change (dry skin).

Injection Superoxide dismutase n = 22

7

9

6

Not reported

No local or systemic adverse effects.

Corsi (1966) [50] Radiotherapy, plesiotherapy plus vitamin E

11 (13 hands)

10 (11 hands)

Case series

4 (N)

Clinical assessment of skin consistency, nodule size and digital extension.

8

3

0

Not reported

Temporary skin rash and epidermolysis noted at end of treatment (number affected not given).

Grenfell (2014) [51] Radiotherapy

6 (4 hands)

3 (4 hands)

Case series

4 (N)

Clinical assessment whether nodule size and hardness

4

0

0

None at 34–42 months

Acute side effects: minimal fatigue, mild local oedema and erythema for total cohort. Number affected and duration not given.

Finney (1953) [52] Radiotherapy

25

7

Case series

4 (N)

Clinical assessment of functional improvement

6

1

0

None at 2–10 years

1st degree reaction: skin dryness, slight erythema for total cohort. Number affected not given.

Finney (1955) [53] Radiotherapy

18

3

Case series

4 (N)

Clinical assessment of functional improvement

3

0

0

Not reported

2nd degree reaction: skin dryness, persistent paraesthesia for total cohort. Number affected not given. Paraesthesia persisting up to 12 months in 2 cases.

  1. Summary of results of radiotherapy treatment for each study, including the number of patients with Dupuytren’s disease in the total cohort in each study, the number of patients with early disease within the total cohort, study type and design, level of evidence according to the Oxford Centre for Evidence Based Medicine (OCEBM) criteria, the outcome measure used and results. The number of hands (in brackets) is stated when availabl, with recurrence and adverse events where stated
  2. aToxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)